Cytek Biosciences, Inc.(CTKB)— Stock Profile, AI Score & Financials

Technology · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Cytek Biosciences, Inc. (CTKB) stock profile, AI quality score, and SEC EDGAR financial data, a Technology sector company. 13F Pro's AI-powered ranking engine scores CTKB at 21.4/100 on a 32-signal composite quality model, placing it at rank #2,769 of 2,962 stocks — the bottom half of the AI-ranked universe. Areas of concern include institutional flow (11.0) and profitability (11.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 14.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Cytek Biosciences, Inc. reports quarterly revenue of $48.1M, net income of $-12.2M, an operating margin of -23.7%. Top institutional holders of CTKB by reported 13-F value include BlackRock, MILLENNIUM MANAGEMENT, Boston Partners, based on the most recent SEC filings. CTKB trades on the Nasdaq exchange and files with the SEC under CIK 1831915. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CTKB daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Cytek Biosciences, Inc. directly from SEC EDGAR.